CHEMED CORP
Chemed (CHE) raised its quarterly dividend to $0.70 per share, payable Sept. 3, 2026, up $0.10 from the prior payment, marking 221 consecutive quarterly payouts. The company reported Q2 2026 net income of $67.7 million and higher EPS year over year. The article links the dividend and earnings beat to Chemed’s capital allocation and 2029 revenue and earnings projections.
Biotech stocks hit 52-week highs Aug. 7, 2026. Halozyme (HALO) rose 20% after Q2 revenue of $481M (+48% Y/Y) and 2026 revenue guidance of $1.83B-$1.91B. Fennec (FENC) reached $11.66 on PEDMARK sales of $15.1M (+71% Y/Y). Avalyn (AVLN) hit $34.15. Amylyx (AMLX) hit $24.60. Chemed (CHE) rose to $552.72 after Q2 revenue $673M (+8.8%) and 2026 growth guidance of 8.25%-9.25%.
MCNAMARA KEVIN J (president and CEO) sold 2,000 shares of CHEMED CORP (CHE) at $539.51 ($1.08M total) on 2026-08-03.
Over the past 7 days, alphai's AI scored 2 news stories mentioning CHE (CHEMED CORP). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent CHE coverage spans insider activity, earnings and financial news.
In the last 30 days, CHE insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($1.2M). The most active reporter was GRACE PATRICK P with 1 filing.
Dividend hike plus an earnings beat supports the capital-return narrative, but the article flags ongoing Medicare Cap risk and Roto Rooter margin/demand pressure as key swing factors.
Updated full-year growth guidance and recent revenue growth are actionable for earnings-model adjustments and valuation multiples.
This is an insider open-market sale by the CEO, with no 10b5-1 plan cited, which can modestly affect near-term sentiment but is not a fundamental change by itself.
The article frames VITAS patient-volume and admission-trend strength plus Roto-Rooter margin resilience despite higher paid-lead marketing.
This is a routine insider sale with no 10b5-1 plan disclosed, but the disclosed size is small relative to typical institutional flows.
alphai scores every news story that mentions CHE with an AI model for sentiment and relevance, and aggregates insider trades from CHEMED CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Chemed (CHE) raised its quarterly dividend to $0.70 per share, payable Sept. 3, 2026, up $0.10 from the prior payment, marking 221 consecutive quarterly payouts. The company reported Q2 2026 net income of $67.7 million and higher EPS year over year. The article links the dividend and earnings beat to Chemed’s capital allocation and 2029 revenue and earnings projections.
6 min readBiotech stocks hit 52-week highs Aug. 7, 2026. Halozyme (HALO) rose 20% after Q2 revenue of $481M (+48% Y/Y) and 2026 revenue guidance of $1.83B-$1.91B. Fennec (FENC) reached $11.66 on PEDMARK sales of $15.1M (+71% Y/Y). Avalyn (AVLN) hit $34.15. Amylyx (AMLX) hit $24.60. Chemed (CHE) rose to $552.72 after Q2 revenue $673M (+8.8%) and 2026 growth guidance of 8.25%-9.25%.
7 min readMCNAMARA KEVIN J (president and CEO) sold 2,000 shares of CHEMED CORP (CHE) at $539.51 ($1.08M total) on 2026-08-03.
2 min readChemed (CHE) reported Q2 CY2026 results that beat Wall Street, helped by VITAS patient volume growth and improved admission trends, and by Roto-Rooter’s commercial programs. Revenue was $673.3M vs $665M est, adjusted EPS $6.06 vs $5.60, and full-year adjusted EPS guidance $25.38 at midpoint. The article highlights analyst questions on VITAS growth sustainability and Roto-Rooter lead costs and margins.
6 min readGRACE PATRICK P sold 190 shares of CHEMED CORP (CHE) at $532.00 ($0.10M total) on 2026-07-31.
1 min readChemed Corp (NYSE:CHE) reported Q2 CY2026 revenue of $673.3 million, up 8.8% year on year and 1.2% above Wall Street estimates, and non-GAAP EPS of $6.06, 8.2% above consensus. Analysts expect revenue growth of about 7% and full-year EPS to rise from $23.40 to $25.61.
5 min readCHEMED CORP (CHE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 che-20260728xex99.htm EX-99 Exhibit 99 CONTACT: Michael D. Witzeman (513) 762- 6714 Chemed Reports Second-Quarter 2026 Results Full-Year Guidance Increased Due Mainly to VITAS Outperformance CINCINNATI, July 28, 2026— Chemed Corporation (Chemed) (NYSE: CHE ), whic
6 min readBarington Capital escalated its activist campaign against Chemed (CHE), calling for a strategic review, cost cuts, and governance changes including a new director. It cited weak oversight and two under-optimized businesses. Investors are watching Medicare reimbursement exposure and Roto Rooter margins. Chemed projects $3.1B revenue and $386.5M earnings by 2029, alongside a $3.05B buyback authorization.
6 min readHazeltree’s H1 2026 Crowding Report says hedge funds stayed heavily positioned in AI infrastructure and semiconductors despite a Middle East conflict and higher inflation. It reports long crowding in Alphabet, Apple and Meta, while short exposure rose in Amazon, Microsoft and Nvidia. Semiconductor net-long share rose from 53% (Feb) to 70% (Jun), with Texas Instruments’ long-to-short ratio up to 2.2.
3 min readLINDELL ANDREA R sold 1,347 shares of CHEMED CORP (CHE) at $447.33 ($0.60M total) on 2026-06-09.
2 min read
